Association between ischemic stroke and pyogenic spondylitis in Korea: Nationwide longitudinal cohort study

Soo Hyun Lee; Hakyung Kim; In-bo Han; Seung Hun Sheen; Je Beom Hong; Seil Sohn

doi:10.7461/jcen.2023.E2022.09.001

J Cerebrovasc Endovasc Neurosurg > Volume 25(2); 2023 > Article

Lee, Kim, Han, Sheen, Hong, and Sohn: Association between ischemic stroke and pyogenic spondylitis in Korea: Nationwide longitudinal cohort study

Clinical Article

Journal of Cerebrovascular and Endovascular Neurosurgery 2023;25(2):143-149.

Published online: January 17, 2023

DOI: https://doi.org/10.7461/jcen.2023.E2022.09.001

Association between ischemic stroke and pyogenic spondylitis in Korea: Nationwide longitudinal cohort study

Soo Hyun Lee¹, Hakyung Kim², In-bo Han¹, Seung Hun Sheen¹, Je Beom Hong³, Seil Sohn¹

¹Department of Neurosurgery, CHA University, CHA Bundang Medical Center, Seongnam, Korea

²Genome & Health Big Data Branch, Department of Public Health, Graduate School of Public Health, Seoul National University, Seoul, Korea

³Department of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to Seil Sohn Department of Neurosurgery, CHA University, CHA Bundang Medical Center, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea Tel +82-31-780-1924 Fax +82-2-780-5269 E-mail seilsohn@gmail.com

Received September 6, 2022 Revised December 31, 2022 Accepted December 31, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective

The purpose of this nationwide age- and sex- matched longitudinal study was to determine the pyogenic spondylitis (PS) increases the incidence of ischemic stroke (IS) in Korea.

Methods

From the National Health Insurance Service (NHIS), we collected the patient data for the period from January 1, 2004 to December 31, 2015. PS was classified according to the International Classification of Disease codes M46.2-M46.8, M49.2, and M49.3. By using a 1:5 age- and sex- stratified matching, a total of 628 patients and 3140 control subjects were included in the study. The IS incidence rates in PS and control group was calculated by using the Kaplan-Meier method. The outcome of hazard ratio of IS was estimated by Cox proportional hazards regression analyses. This study did not exclude PS as a result of postoperative complications.

Results

According to the study, 51 patients (8.12%) in the PS group and 201 patients (6.4%) in the control group experienced IS. The adjusted hazard ratio of IS in the PS group was 3.419 (95% CI: 2.473-4.729) after adjusting individual medical condition and demographics. Following the results of subgroup analysis, the risk ratio of IS was greater in most of the subgroup categories (male, female, age <65, age >65, non-diabetic, hypertensive, non-hypertensive, dyslipidemic and non-dyslipidemic subgroup). However, the risk of IS did not differ significantly in diabetic subgroup (95% CI: 0.953-4.360).

Conclusions

The risk rate of IS increased in patient with pyogenic spondylitis.

Keywords: Pyogenic spondylitis, Ischemic stroke, Epidemiology, Population

INTRODUCTION

Pyogenic spondylitis (PS) is rare disease that covers a broad range of clinical area including pyogenic spondylodiscitis, septic discitis, vertebral osteomyelitis, and epidural abscess [3,13,15,16,26]. However, the incidence of PS is increasing due to the increase in the elderly and immunocompromised patients [3,13,26]. Several studies have been conducted on the relationship between PS and infection [3,15,16,26]. It is usually caused by hematogenous spread of bacteria [3,14,26]. However, there were no studies and information on the direct relationship between the increase in ischemic stroke (IS) by PS. This nationwide longitudinal study was conducted to clarify whether the infectious disease, PS, increases the incidence of IS. This study did not exclude PS as a result of postoperative complications.

MATERIALS AND METHODS

Data source

In Korea, single payer health insurance system is managed by National Health Insurance System (NHIS) [16,17,23]. Regular and part-time workers over the age of 40 are recommended to undergo regular health checkups every 1 or 2 years. The collected information (e.g., demographic profile, health insurance claims, national health examination results and death certificates) is saved in National Health Information Database (NHID). For this study, data from 2004 to 2015 were provided from NHIS-HEALS cohort. We were able to access the data legally for research purposes with the approval of the institutional review boards (IRB No. 2020-01-011).

Establishment of the study cohort

The group diagnosed with PS according to the ICD-10 code (M46.2-M46.8, M49.2-M49.3) was included in the PS group. Only 10,890 PS subjects were selected out of a total of 15,547 patients in the NHISS database. By excluding those diagnosed with PS before Jan. 1, 2004 and 10,237 patients who had never been hospitalized, a group of 628 patients newly diagnosed with PS after Jan. 1, 2004 could be derived and were monitored until Dec. 31, 2015. By using the greedy matching algorithm of the ‘Match IT’ R package, 3,140 people were selected as a control group in 1:5 age- and sex- stratified matching (without replacement) [18,19]. The patient groups included in this study were followed from the first diagnosis of IS until death or the end of the study (Fig. 1). Among the PS and control group, IS patients were selected by using the following criteria: ICD-10 codes (I63 or I64), IS confirmed by brain CT or MRI scan and hospitalization ≥1 day [17,18]. The risk of IS was evaluated by adjusting for other factors such as age, sex and comorbidities (hypertension, diabetes mellitus, and dyslipidemia), and values could be derived accordingly.

Statistical analysis

The chi-squared tests and student’s t-test were used to evaluate the demographic diversity and characteristics between the PS group and the control group. The Kaplan-Meier method was able to calculate the viability without IS in each group. The differences in diseasefree survival among the two groups were assessed by using the Wilcoxon’s log rank test. Multivariate analysis of the Cox proportional hazard regression model was performed to determine the effect of PS on IS. Two Cox proportional hazard regression models were designed and analyzed through R software (version 3.3.3, The R Foundation for Statistical Computing, Vienna, Austria). For Model 1, age and sex were adjusted, and for Model 2, age, sex, and underlying disease were adjusted. To adjust covariates, we conducted subgroup analyses.

RESULTS

Characteristics of the PS and control group

For the PS group, 628 patients newly diagnosed with PS were selected and 3140 patients were selected for the control group. Of these, 323 patients (51.43%) were male and 199 patients (48.57%) were female. The mean age of the patients was 59.09±9.35 years. In the presence of diabetes, there was difference in prevalence between the two groups (P<0.01) (Table 1).

IS in the PS and control group

The likelihood of the occurrence of IS was higher in the PS group than that of IS in the control group. Through the Kaplan-Meier curves, the cumulative incidence of IS was higher in the PS group (Fig. 2). Multivariate analysis of Cox proportional hazards regression Model 1 showed that the IS hazard ratio for the PS group was 3.518 compared to the control group (95% CI: 2.546-4.801, Table 2). In the Model 2, the IS hazard ratio was 3.419 compared to the control group (95% CI: 2.473-4.729, Table 2).

Subgroup analysis of IS incidence rate

The IS incidence rate was different between PS and control group in both of male (95% CI: 1.953-4.935, Table 3) and female subgroup (95% CI: 2.517-6.207, Table 3). The incidence of IS was significantly different between PS and control group in both of age <65 (95% CI: 3.173-7.731, Table 3) and age >65 subgroup (95% CI: 1.473-3.852, Table 3). The IS incidence rate was different in both of non-hypertensive (95% CI: 2.045-5.183, Table 3) and hypertensive subgroup (95% CI: 2.373-5.826, Table 3). Furthermore, the incidence of IS was significantly different in non-dyslipidemic (95% CI: 2.509-4.960, Table 3), dyslipidemic (95% CI: 1.165-8.768, Table 3) and non-diabetic subgroup (95% CI: 2.652-5.414, Table 3). However, there was no significant difference between PS and control group in diabetic subgroup (95% CI: 0.953-4.360, Table 3).

DISCUSSION

According to our study, there was 3.518 fold increased incidence of IS after adjusting sex and age and 3.419 fold increased incidence of IS after adjusting sex, age, and underlying disease (diabetic, dyslipidemia, hypertension). The study results showed that the incidence of IS was higher in the PS group in male, female, under 65 years of age, over 65 years of age, non-diabetic, non-dyslipidemic, dyslipidemic, non-hypertensive and hypertensive.

PS is an uncommon spinal infection that can give patients a serious and life-threatening condition [3,15,16,26]. The most common organism of PS is S. aureus [3,13,15,16,26]. Research on PS reports diabetes mellitus (DM), long-term steroid therapy, substance abuse, malnutrition, malignancy, liver cirrhosis and HIV as risk factors [4,12,14,15,26]. Currently, there is a lack of research and information on the direct relationship between PS and IS. However, several studies have been conducted on the link between infection and IS. Acute and chronic infections have been reported to accelerate the progression of atherosclerosis, leading to acute ischemic stroke [7,11,12,17,18,29]. Grau et al. [10] reported bacterial infections significantly increased the risk for cerebrovascular ischemia (95% CI, 2.0 to 16.9; P<.002). In addition, it has been reported that C-reactive protein (CRP) can be used as a strong indicator in relation to vascular disease [5,9]. Increased lipoprotein and plasminogen activator inhibitor-1 can be used as biomarkers for the progression of intracranial atherosclerotic disease [1,2,6,10,12,17,20,22,25,29,30]. Ross et al. [25] reported that inflammation is associated with an increase in fibrinogen and CRP, both of which are associated with an early sign of atherosclerosis. In addition to that, interleukin-6 (IL-6) was reported as a major inflammatory cytokine associated with a predictive marker of stroke risk [8,9,20,21,24]. Although infection increases the risk of IS, it has been reported that IS increases the risk of infection by inducing immunosuppression [7,12,27,28]. Several studies have shown that infection and IS are closely related [4,7,8,10,12,21,24,27-29].

Interpretation of the graph (Fig. 2) becomes possible through these inflammatory factors. It can be seen that the slope of the graph is steep in the early stage of diagnosis, because IS occurred in many patients due to atherosclerotic changes caused by inflammatory factors. A delayed onset of IS was seen in the remaining patients with intracranial atherosclerotic changes. Therefore, it can be seen that the slope of the graph becomes smoother over time. Near the end of the follow-up period, it shows a flat slope which indicates no accumulation of IS after a long period of time. This is because the IS had already occurred at the beginning and middle of the follow-up period.

Since PS is a disease caused by infection of the spine, it can be expected that the risk of IS may be increased. However, further studies are needed to elucidate the direct causes and mechanisms.

There are several limitations in our study. First, this study was conducted by classifying gender, age, and underlying disease in the NHIS database, and did not include individual lifestyles (Alcohol, tobacco, regular diet and exercise, etc.) [18,19] and biomarkers (CRP, IL-6, fibrinogen, lipoprotein, and plasminogen activator inhibitor-1 etc.) [1,2,6,8,10,12,17,20-22,24,25,29,30]. Second, information on the clinical severity of individual PS patients was not included in the data. Further studies may be required due to the difficulties in randomization to various factors not included in the data.

While there may be shortcomings in several areas, this is the largest nationwide longitudinal study showing an increased risk of IS in patients with PS.

CONCLUSIONS

Through this nationwide longitudinal study, it was found that the risk of IS was increased in PS patients.

ACKNOWLEDGEMENTS

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A1A01072258). This work was also supported by a grant of Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-2020R1F1A1069875).

NOTES

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Fig. 1.

Flow of cohort formation process. This study was a 12-year longitudinal cohort study completed on the basis of the NHIS-HEALS cohort. NHISS, National Health Insurance Service-Health Screening; NHIS, National Health Insurance Service

Fig. 2.

The Kaplan-Meier curves with cumulative incidence of ischemic stroke in the pyogenic spondylitis and control groups.

Table 1.

Characteristics in the PS and control group

Variables	PS (n=628)	Control (n=3,140)	P
Male	323 (51.43%)	1,615 (51.43%)
Age	59.09±9.35	59.09±9.35
Age≥65	199 (31.69%)	995 (31.69%)
Low income	161 (25.64%)	840 (26.75%)	0.6
Diabetes	83 (13.22%)	289 (9.20%)	<0.01
Hypertension	268 (42.68%)	1,241 (39.52%)	0.15
Dyslipidemia	99 (15.76%)	486 (15.48%)	0.9

Bold style indicates statistical significance.

PS, pyogenic spondylitis

Table 2.

Adjusted hazard ratio for IS in the PS and control group

Disease	Group	N	Event	Duration (days)	Incidence rate (1000 person-year)	Hazard ratio (95% CI)
Disease	Group	N	Event	Duration (days)	Incidence rate (1000 person-year)	Model 1	Model 2
IS	Control	3,140	201	12,667,251	2.618	1	1
IS	PS	628	51	912,115	9.226	3.518 (2.546, 4.801)	3.419 (2.473, 4.729)

Model 1: Adjusted for age, sex.

Model 2: Adjusted for age, sex, low income, diabetes, hypertension, dyslipidemia.

IS, ischemic stroke; PS, pyogenic spondylitis; CI, confidence interval

Table 3.

IS incidence rate in subgroup analyses between PS and control group

Variables		PS		Control		Hazard ratio (95% CI)
Variables		N	Incidence rate (%)	N	Incidence rate (%)	Hazard ratio (95% CI)
Sex	Male	7	3.352	16	1.997	3.105 (1.953, 4.935)
Sex	Female	9	4.596	27	1.100	3.953 (2.517, 6.207)
Age	<65	6	4.126	5	1.024	4.953 (3.173, 7.731)
Age	≥65	10	3.740	38	2.724	2.382 (1.473, 3.852)
Diabetes	N	3	2.788	9	1.422	3.789 (2.652, 5.414)
Diabetes	Y	13	11.529	34	2.620	2.038 (0.953, 4.360)
Hypertension	N	9	2.690	21	0.897	3.255 (2.045, 5.183)
Hypertension	Y	7	5.930	22	2.515	3.718 (2.373, 5.826)
Dyslipidemia	N	3	3.761	10	1.468	3.528 (2.509, 4.960)
Dyslipidemia	Y	13	5.380	33	1.850	3.196 (1.165, 8.768)

IS, ischemic stroke; PS, pyogenic spondylitis; CI, confidence interval

REFERENCES

1. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res. 2017 Feb;120(3):502-13.

2. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke. 1996 Dec;27(12):2204-6.

3. Cheung WY, Luk KDK. Pyogenic spondylitis. Int Orthop. 2012 Feb;36(2):397-404.

4. Cowan LT, Alonso A, Pankow JS, Folsom AR, Rosamond WD, Gottesman RF, et al. Hospitalized infection as a trigger for acute ischemic stroke: the atherosclerosis risk in communities study. Stroke. 2016 Jun;47(6):1612-7.

5. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001 Jan;32(1):133-8.

6. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005 Aug;109(2):171-6.

7. Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020 51(10):3156-68.

8. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab. 2002 Dec;22(12):1399-419.

9. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2355-63.

10. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995 Mar;26(3):373-9.

11. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis. 1989 Jun;77(2-3):209-13.

12. Ionita CC, Siddiqui AH, Levy EI, Hopkins LN, Snyder KV, Gibbons KJ. Acute ischemic stroke and infections. J Stroke Cerebrovasc Dis. 2011 Jan-Feb;20(1):1-9.

13. Jeong DK, Lee HW, Kwon YM. Clinical value of procalcitonin in patients with spinal infection. J Korean Neurosurg Soc. 2015 Sep;58(3):271-5.

14. Jeong SJ, Choi SW, Youm JY, Kim HW, Ha HG, Yi JS. Microbiology and epidemiology of infectious spinal disease. J Korean Neurosurg Soc. 2014 Jul;56(1):21-7.

15. Kim YJ, Hong JB, Kim YS, Yi J, Choi JM, Sohn S. Change of pyogenic and tuberculous spondylitis between 2007 and 2016 year: a nationwide study. J Korean Neurosurg Soc. 2020 Nov;63(6):784-93.

16. Kim YS, Kim JG, Yi J, Choi JM, Chung CK, Choi UY, et al. Changes in the medical burden of pyogenic and tuberculous spondylitis between 2007 and 2016: a nationwide cohort study. J Clin Neurosci. 2020 Mar;73:89-93.

17. Lee DH, Choi YJ, Han IB, Hong JB, Han KD, Choi JM, et al. Association of ischemic stroke with ankylosing spondylitis: a nationwide longitudinal cohort study. Acta Neurochir (Wien). 2018 May;160(5):949-55.

18. Lee DH, Sheen SH, Lee DG, Jang JW, Lee DC, Shin SH, et al. Association between ischemic stroke and seropositive rheumatoid arthritis in Korea: a nationwide longitudinal cohort study. PloS One. 2021 May;16(5):e0251851.

19. Lee JK, Kim H, Hong JB, Sheen SH, Han IB, Sohn S. Association of acute myocardial infarction with seropositive rheumatoid arthritis in Korea: a nationwide longitudinal cohort study. J Clin Neurosci. 2020 Aug;78:97-101.

20. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1263-8.

21. McColl B, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience. 2009 Feb;158(3):1049-61.

22. Palm F, Pussinen PJ, Aigner A, Becher H, Buggle F, Bauer MF, et al. Association between infectious burden, socioeconomic status, and ischemic stroke. Atherosclerosis. 2016 Nov;254:117-23.

23. Park CJ, Choi YJ, Kim JG, Han IB, Han KD, Choi JM, et al. Association of acute myocardial infarction with ankylosing spondylitis: a nationwide longitudinal cohort study. J Clin Neurosci. 2018 Oct;56:34-7.

24. Rodríguez-Yáñez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol. 2008 Jun;21(3):353-7.

25. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999 Jan;340(2):115-26.

26. Sato K, Yamada K, Yokosuka K, Yoshida T, Goto M, Matsubara T, et al. Pyogenic spondylitis: clinical features, diagnosis and treatment. Kurume Med J. 2019 Sep 25 65(3):83-9.

27. Sebastian S, Stein LK, Dhamoon MS. Infection as a stroke trigger: associations between different organ system infection admissions and stroke subtypes. Stroke. 2019 Aug;50(8):2216-8.

28. Shao IY, Elkind MS, Boehme AK. Risk factors for stroke in patients with sepsis and bloodstream infections. Stroke. 2019 May;50(5):1046-51.

29. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006 Jul;37(7):1923-32.

30. Stone M, Thorp J. Plasma fibrinogen—a major coronary risk factor. J R Coll Gen Pract. 1985 Dec;35(281):565-9.